This suggests that KRAS, but not BRAF mutations provide a selective advantage specifically in APC-mutant CRC precursor cells, whereas FBXW7 mutations provide the greatest advantage for CRC cells harboring activated BRAF. The gene discussed is KRAS; the disease is colorectal carcinoma.